Patents by Inventor Yong Yea PARK

Yong Yea PARK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240140944
    Abstract: The present invention relates to a novel naphthyridinone derivative compound, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof, which are each relevant to a compound for inhibiting ENPP1, a composition for inhibiting ENPP1, and a method for inhibiting ENPP1.
    Type: Application
    Filed: December 29, 2021
    Publication date: May 2, 2024
    Applicant: TXINNO BIOSCIENCE INC.
    Inventors: Seo Jung Han, Chan Sun Park, Sung Joon Kim, Jae Eun Cheong, Jung Hwan Choi, Ali Imran, Sun Woo Lee, Yong Yea Park, Ah Ran Yu, Sun Young Park
  • Publication number: 20240116882
    Abstract: The present invention relates to a novel benzotriazole derivative compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof, which are related to a compound for inhibiting ENPP1, a composition for inhibiting ENPP1, and a method for inhibiting ENPP1.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 11, 2024
    Applicant: TXINNO BIOSCIENCE INC.
    Inventors: Chan Sun Park, Sung Joon Kim, Ali Imran, Yoo Jin Na, So Ra Paik, Jung Hwan Choi, Sun Woo Lee, Yong Yea Park, Ah Ran Yu, Sun Young Park
  • Publication number: 20220251176
    Abstract: A fusion protein including a fragment of an anti-mesothelin antibody, an anti-CD3 antibody or an anti-EGFR antibody; a bispecific antibody that is specific to mesothelin and CD3; a trispecific antibody that is specific to mesothelin, CD3 and EGFR are provided. The fusion protein is effective in treating cancer. The bispecific or trispecific antibody can be prepared in a high yield and with high purity, and has excellent tumor killing and growth inhibitory effects, and thus can be effectively used in cancer treatment.
    Type: Application
    Filed: December 16, 2019
    Publication date: August 11, 2022
    Applicants: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Yangmi LIM, Shinai LEE, Jonghwa WON, Yong-Yea PARK, Aerin YOON, Sua LEE, Okjae LIM, Sojung LIM, Munkyung KIM
  • Patent number: 11401343
    Abstract: The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 2, 2022
    Assignees: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Ki Su Kim, Jung Hong Jeong, Dong Sik Kim, Yang Mi Lim, Yong Yea Park, Hyung Kwon Lim, Jong Wha Won
  • Publication number: 20200262928
    Abstract: The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.
    Type: Application
    Filed: October 22, 2018
    Publication date: August 20, 2020
    Applicants: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Ki Su KIM, Jung Hong JEONG, Dong Sik KIM, Yang Mi LIM, Yong Yea PARK, Hyung Kwon LIM, Jong Wha WON